Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$33.37

-4.01 (-10.73%)

11:00
10/02/17
10/02
11:00
10/02/17
11:00

Biohaven target lowered to $36 on failed study at Needham

Needham analyst Alan Carr lowered his price target for Biohaven Pharmaceutical to $36 from $43 after the company reported the trigriluzole Phase 2/3 trial in spinocerebellar ataxia missed the primary endpoint. The analyst removed the program from his model but continues to expect a positive Phase 3 readout for rimegepant in Q1 of 2018. Carr keeps a Buy rating on Biohaven.

BHVN Biohaven Pharmaceutical
$33.37

-4.01 (-10.73%)

05/31/17
MSCO
05/31/17
INITIATION
Target $28
MSCO
Overweight
Biohaven Pharmaceutical initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated Biohaven Pharmaceutical with an Overweight and a $28 price target.
08/15/17
NEED
08/15/17
NO CHANGE
Target $30
NEED
Buy
Needham sees favorable risk/benefit around Bihaven Trigriluzole results
Needham analyst Alan Carr notes that randomization in Phase 2/3 trial of Biohaven Pharmaceutical's trigriluzole in Spinocerebellar Ataxia was completed earlier this month, with results expected to be available Q4. The analyst is biased toward a positive outcome based on previous reports of riluzole activity in this indication. Further, Carr believes this program is underappreciated by investors, who are mostly focused on rimegepant Migraine program. He reiterates a Buy rating and $30 price target on the shares.
09/13/17
NEED
09/13/17
NO CHANGE
NEED
Biohaven Pharmaceutical price target raised to $43 from $30 at Needham
Needham analyst Alan Carr raised his price target on Biohaven as he is increasingly optimistic that a Phase 2/3 trial of the company's trigriluzole drug will yield positive data. He keeps a Buy rating on the stock.
09/25/17
MSCO
09/25/17
NO CHANGE
Target $47
MSCO
Overweight
Biohaven price target raised to $47 from $28 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Phase 2/3 data from trigriluzole in spinocerebellar ataxia, the lead program within Biohaven Pharmaceutical's glutamate platform, is expected in Q4. The analyst, who assigns a 75% chance of success, believes his previous estimates for trigriluzole in SCA were too conservative and now sees it reaching long-term share of about 50% given the lack of other therapies. He raised his price target on Biohaven to $47 from $28 and keeps an Overweigh rating on the stock.

TODAY'S FREE FLY STORIES

RAIL

FreightCar America

$16.66

0.09 (0.54%)

14:22
07/18/18
07/18
14:22
07/18/18
14:22
Hot Stocks
Breaking Hot Stocks news story on FreightCar America »

Russell Investments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
07/18/18
07/18
14:20
07/18/18
14:20
General news
Fed's Beige Book reported economic activity continued to expand »

Fed's Beige Book…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/18/18
07/18
14:17
07/18/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADTN

Adtran

$16.20

0.15 (0.93%)

14:17
07/18/18
07/18
14:17
07/18/18
14:17
Downgrade
Adtran rating change  »

Adtran downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/18/18
07/18
14:16
07/18/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.80

0.38 (0.14%)

14:15
07/18/18
07/18
14:15
07/18/18
14:15
General news
Manufacturers in all Fed districts expressed concern about tariffs »

The Federal Reserve said…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.80

0.38 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PENN

Penn National

$35.05

-0.65 (-1.82%)

14:05
07/18/18
07/18
14:05
07/18/18
14:05
Options
Penn National call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.81

0.39 (0.14%)

14:02
07/18/18
07/18
14:02
07/18/18
14:02
General news
Employment continued to rise at 'modest to moderate pace,' Fed says »

The Federal Reserve said…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.81

0.39 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.81

0.39 (0.14%)

14:01
07/18/18
07/18
14:01
07/18/18
14:01
General news
Fed says economic activity continued to expand across the U.S. »

The Federal Reserve said…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.81

0.39 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,200.65

1.84 (0.15%)

, GOOGL

Alphabet Class A

$1,218.02

4.37 (0.36%)

14:00
07/18/18
07/18
14:00
07/18/18
14:00
Hot Stocks
Alphabet to take Q2 charge of $5.07B for European Commission fine »

Alphabet in a press…

GOOG

Alphabet

$1,200.65

1.84 (0.15%)

GOOGL

Alphabet Class A

$1,218.02

4.37 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

13:55
07/18/18
07/18
13:55
07/18/18
13:55
Conference/Events
House Financial Services Committee to hold a hearing »

The Monetary Policy &…

GLW

Corning

$29.31

0.12 (0.41%)

13:54
07/18/18
07/18
13:54
07/18/18
13:54
Hot Stocks
Corning introduces Gorilla Glass 6, 'most durable cover glass to date' »

Corning introduced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TSLA

Tesla

$321.21

-1.58 (-0.49%)

13:50
07/18/18
07/18
13:50
07/18/18
13:50
Periodicals
Germany asks Tesla owners to pay back EUR 4000 incentive, electrek says »

Tesla's ongoing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

13:45
07/18/18
07/18
13:45
07/18/18
13:45
General news
Fed Chairman Powell's 2-day semi-annual testimony has concluded »

Fed Chairman…

13:45
07/18/18
07/18
13:45
07/18/18
13:45
General news
Breaking General news story  »

June Beige Book to be…

GM

General Motors

$39.90

-0.15 (-0.37%)

, FCAU

Fiat Chrysler

$19.37

-0.295 (-1.50%)

13:42
07/18/18
07/18
13:42
07/18/18
13:42
Periodicals
The U.S. auto industry aligned in push back on tariffs, WSJ says »

The U.S. auto complex,…

GM

General Motors

$39.90

-0.15 (-0.37%)

FCAU

Fiat Chrysler

$19.37

-0.295 (-1.50%)

DLPH

Delphi Technologies

$45.78

0.87 (1.94%)

BWA

BorgWarner

$46.47

0.8 (1.75%)

MGA

Magna

$61.62

1.03 (1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 18

    Sep

HPQ

HP Inc.

$23.38

-0.22 (-0.93%)

13:40
07/18/18
07/18
13:40
07/18/18
13:40
Options
Short-term put buying in H-P »

Short-term put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
07/18/18
07/18
13:30
07/18/18
13:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

13:25
07/18/18
07/18
13:25
07/18/18
13:25
General news
Treasury Action: yields rebounded from lows »

Treasury Action: yields…

AMGN

Amgen

$193.08

-0.85 (-0.44%)

13:25
07/18/18
07/18
13:25
07/18/18
13:25
Conference/Events
Brookings hosts a conversation with FDA Commisioner Gottlieb »

The USC-Brookings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

GSK

GlaxoSmithKline

$41.00

-0.145 (-0.35%)

, PFE

Pfizer

$37.63

-0.04 (-0.11%)

13:23
07/18/18
07/18
13:23
07/18/18
13:23
Hot Stocks
GSK's ViiV to share data from landmark 2-drug regimen trials at AIDS 2018 »

ViiV Healthcare, the…

GSK

GlaxoSmithKline

$41.00

-0.145 (-0.35%)

PFE

Pfizer

$37.63

-0.04 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 22

    Aug

  • 10

    Sep

RHT

Red Hat

$147.95

0.43 (0.29%)

13:20
07/18/18
07/18
13:20
07/18/18
13:20
Options
Notable position opened in RedHat »

Notable position opened…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/18/18
07/18
13:17
07/18/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/18/18
07/18
13:16
07/18/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGP

GGP

$20.45

-0.25 (-1.21%)

13:15
07/18/18
07/18
13:15
07/18/18
13:15
Options
General Growth put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.